Serum Cotinine and Adverse Cardiovascular Outcomes: A Cross-sectional Secondary Analysis of the nuMoM2b Heart Health Study

dc.contributor.authorTheilen, Lauren H.
dc.contributor.authorMcNeil, Rebecca B.
dc.contributor.authorHunter, Shannon
dc.contributor.authorGrobman, William A.
dc.contributor.authorParker, Corette B.
dc.contributor.authorCatov, Janet M.
dc.contributor.authorPemberton, Victoria L.
dc.contributor.authorEhrenthal, Deborah B.
dc.contributor.authorHaas, David M.
dc.contributor.authorHoffman, Matthew K.
dc.contributor.authorChung, Judith H.
dc.contributor.authorMukhtar, Farhana
dc.contributor.authorArzumanyan, Zorayr
dc.contributor.authorMercer, Brian
dc.contributor.authorParry, Samuel
dc.contributor.authorSaade, George R.
dc.contributor.authorSimhan, Hyagriv N.
dc.contributor.authorWapner, Ronald J.
dc.contributor.authorSilver, Robert M.
dc.contributor.authorNHLBI nuMoM2b Heart Health Study Network
dc.contributor.departmentObstetrics and Gynecology, School of Medicine
dc.date.accessioned2024-08-07T08:38:16Z
dc.date.available2024-08-07T08:38:16Z
dc.date.issued2023
dc.description.abstractObjective: We aimed to (1) compare serum cotinine with self-report for ascertaining smoking status among reproductive-aged women; (2) estimate the relative odds of adverse cardiovascular (CV) outcomes among women by smoking status; (3) assess whether the association between adverse pregnancy outcomes (APOs) and CV outcomes varies by smoking status. Study design: We conducted a cross-sectional study of the nuMoM2b Heart Health Study. Women attended a study visit 2 to 7 years after their first pregnancy. The exposure was smoking status, determined by self-report and by serum cotinine. Outcomes included incident chronic hypertension (HTN), metabolic syndrome (MetS), and dyslipidemia. Multivariable logistic regression estimated odds ratios (ORs) for each outcome by smoking status. Results: Of 4,392 women with serum cotinine measured, 3,610 were categorized as nonsmokers, 62 as secondhand smoke exposure, and 720 as smokers. Of 3,144 women who denied tobacco smoke exposure, serum cotinine was consistent with secondhand smoke exposure in 48 (1.5%) and current smoking in 131 (4.2%) After adjustment for APOs, smoking defined by serum cotinine was associated with MetS (adjusted OR [aOR] = 1.52, 95% confidence interval [CI]: 1.21, 1.91) and dyslipidemia (aOR = 1.28, 95% CI: 1.01, 1.62). When stratified by nicotine exposure, nonsmokers with an APO in their index pregnancy had higher odds of stage 1 (aOR = 1.64, 95% CI: 1.32, 2.03) and stage 2 HTN (aOR = 2.92, 95% CI: 2.17, 3.93), MetS (aOR = 1.76, 95% CI: 1.42, 2.18), and dyslipidemia (aOR = 1.55, 95% CI: 1.25, 1.91) relative to women with no APO. Results were similar when smoking exposure was defined by self-report. Conclusion: Whether determined by serum cotinine or self-report, smoking is associated with subsequent CV outcomes in reproductive-aged women. APOs are also independently associated with CV outcomes in women.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationTheilen LH, McNeil RB, Hunter S, et al. Serum Cotinine and Adverse Cardiovascular Outcomes: A Cross-sectional Secondary Analysis of the nuMoM2b Heart Health Study. Am J Perinatol. 2023;40(12):1311-1320. doi:10.1055/a-1580-3155
dc.identifier.urihttps://hdl.handle.net/1805/42687
dc.language.isoen_US
dc.publisherThieme
dc.relation.isversionof10.1055/a-1580-3155
dc.relation.journalAmerican Journal of Perinatology
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectPregnancy
dc.subjectCross-sectional studies
dc.subjectTobacco smoke
dc.subjectNicotine
dc.subjectSmokers
dc.subjectPregnancy outcome
dc.subjectCardiovascular diseases
dc.titleSerum Cotinine and Adverse Cardiovascular Outcomes: A Cross-sectional Secondary Analysis of the nuMoM2b Heart Health Study
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Theilen2023Serum-AAM.pdf
Size:
660.99 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: